Reviews/Psoriasis Psoriatic Arthritis/Ixekizumab versus adalimumab ACR50 in psoriatic arthritis
Psa PJT · PSA-PJT-01 · v2
The claim says ixekizumab beats adalimumab on the ACR50 joint-response measure in patients who have not previously had a biologic drug. The only direct comparison of the two drugs [1] found that on ACR50 specifically ixekizumab was non-inferior — meaning as good as, not better — with 51% versus 47%. Where ixekizumab did win was on the skin measure (PASI100) and on a combined joint-plus-skin target, not on the joint measure standing alone [1][2]. A follow-up report [2] states joint improvements were comparable between the two drugs. Because the claim asserts standalone ACR50 superiority, which the direct evidence explicitly labels non-inferiority, the panel found the claim as worded contradicted by the evidence.
The single head-to-head trial [1] reports ixekizumab non-inferior on ACR50 (IXE 51%, ADA 47%, treatment difference 3.9%) while superior on PASI100 (60% vs 47%, p=0.001) and on the simultaneous ACR50+PASI100 primary endpoint (36% vs 28%, p=0.036). The 52-week extension [2] confirms more ixekizumab patients simultaneously achieved PASI100 and ACR50, but states joint symptom improvements were comparable between groups. The methotrexate-subgroup analysis [3] found ixekizumab superior on the combined endpoint only when used without methotrexate. The consistency analysis [7] reports a numerically higher proportion of ixekizumab patients maintaining ACR50 over time, but this is descriptive rather than a superiority test. The contested point: The evidence divides on which endpoint carries the superiority signal: ixekizumab is superior on the skin measure PASI100 and on the combined ACR50+PASI100 co-primary [1], but only non-inferior on standalone ACR50 [1], with joint improvements described as comparable [2]. The claim's wording attaches superiority to ACR50 alone, which the corpus does not support.
All 8 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Psoriasis Psoriatic Arthritis, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The primary head-to-head [1] explicitly designates the ACR50 result non-inferior (51% vs 47%, 3.9% difference); the claim relabels this as superiority — a direct contradiction of the exact wording.
The trial's superiority signal is on PASI100 (skin) and the simultaneous ACR50+PASI100 co-primary; attributing standalone ACR50 superiority conflates the joint endpoint with the skin-driven composite.
Where it remains uncertain. Ixekizumab's superiority signal lives in the skin and combined endpoints [1], while joint improvements were comparable between groups [2] — so standalone ACR50 superiority is not demonstrated.
Aleatory
The 3.9% difference between IXE (51%) and ADA (47%) on ACR50 [1] is small relative to expected trial-to-trial sampling variation, so even the numerical direction could reverse in a repeat.
Epistemic
All comparative evidence derives from SPIRIT-H2H [1][2][3][7]; no independent replication exists to confirm even a numerical ACR50 difference.
Inferential
The trial's superiority attaches to PASI100 and the combined ACR50+PASI100 endpoint [1]; reading standalone ACR50 superiority from that requires an inferential leap the data do not license.
The load-bearing papers from a corpus of 8, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
At 52 weeks joint (ACR-domain) response is comparable, contradicting ACR50 superiority.
“Joint symptom improvements were comparable between groups.”
Panel auditInternal validity: medium · scope of inference: Biologic-naive PsA with moderate-to-severe psoriasis, 52-week joint versus skin response IXE vs ADA.Key limitations: ACR50 only reported within combined endpoint · no isolated ACR50 statistics · combined endpoint confounded by skin response
Any comparative edge is on the combined endpoint and modified by MTX, not standalone ACR50 superiority.
“By week 52, IXE provided similar improvements in the combined ACR50 and PASI100 endpoint and ACR50 regardless of whether IXE was used with or without MTX, while ADA efficacy appeared improved with concomitant MTX use.”
Panel auditInternal validity: medium · scope of inference: Biologic-naive PsA, effect of concomitant MTX on IXE versus ADA response at 52 weeks.Key limitations: cross-drug result reported only on combined endpoint · post-hoc subgroup by MTX · no isolated ACR50 IXE vs ADA numbers
Direct head-to-head: ACR50 result is non-inferiority, not superiority; superiority is on PASI100.
“IXE was non-inferior for ACR50 response (IXE: 51%, ADA: 47%; treatment difference: 3.9%) and superior for PASI100 response (IXE: 60%, ADA: 47%; p=0.001).”
Panel auditInternal validity: medium · scope of inference: Biologic-naive active PsA with moderate-to-severe psoriasis, 24-week ACR50 response IXE vs ADA.Key limitations: open-label design · no significance test for ACR50 alone · primary endpoint was combined ACR50+PASI100, not ACR50 alone
Only a numerical maintenance difference, not a powered superiority finding on ACR50.
“A numerically higher proportion of IXE versus ADA patients show consistency of ACR50 response over time.”
Panel auditInternal validity: medium · scope of inference: Consistency of ACR50 maintenance among Wk 24 ACR50 responders, IXE vs ADA — durability, not achievement rate.Key limitations: numerical difference only, no significance test · conditioned on Wk 24 responders · measures maintenance not achievement of ACR50
4 of 8 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
The direct comparative evidence explicitly designates ACR50 as non-inferior rather than superior, refuting the claim as worded.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No powered standalone-ACR50 superiority test. The direct trial [1] designed ACR50 as a non-inferiority comparison, so the claim's exact assertion was never formally tested for superiority. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A head-to-head trial pre-specifying and powered for ACR50 superiority as a primary endpoint.
Open question: Is ixekizumab superior to adalimumab on standalone ACR50 when the endpoint is pre-specified and powered for superiority? Why it is still open: The only direct trial [1] tested ACR50 for non-inferiority, not superiority, and reported a 3.9% difference without a superiority claim.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 18 Sep 2026 · protocol v0.19